Can Fish Help Unlock Better Cancer Treatments?

A groundbreaking clinical trial in Portugal aims to explore whether zebrafish can pave the way for more effective cancer therapies. Led by the Champalimaud Foundation, this five-year study marks the first randomized trial in which patients will receive treatments tested on zebrafish embryos implanted with their own cancer cells. Previous retrospective studies suggest that this "zavatar" technology—short for zebrafish avatar—can accurately identify successful treatment options. Researchers hope the trial will confirm its potential to deliver real benefits to patients.

Oncologists often face significant challenges in selecting treatments due to the unique characteristics of each patient’s tumor, including genetic, metabolic, and growth variations. Without precise tools, patients may endure multiple harmful therapies before finding an effective one. While genomic analysis can highlight potential treatments, even the presence of specific mutations does not guarantee success.

To address this, researchers have spent the past decade refining the zavatar technique. The process involves isolating cancer cells from a patient, tagging them with fluorescent markers, and implanting them into transparent zebrafish embryos, which can develop naturally outside the mother’s body. Anti-cancer drugs or radiation are then applied to the fish, allowing researchers to observe the response of the fluorescent tumor cells and assess the tumor’s sensitivity to various treatments.

If successful, this innovative approach could revolutionize personalized cancer therapy, offering a more reliable method to tailor treatments to individual patients.